Network meta-analysis treatment ranking results for function outcome analyses, for each of short-term outcomes, medium-term outcomes and long-term outcomes
| Treatment | Short-term function | Medium-term function | Long-term function | |||
| SUCRA | Mean rank | SUCRA | Mean rank | SUCRA | Mean rank | |
| ESWT | 69.5 | 2.5 | 65.6 | 2.7 | 72.8 | 2.1 |
| Exe | 32.2 | 4.4 | 29.9 | 4.5 | 82.1 | 1.7 |
| Orthoses | 31.8 | 4.4 | 42.4 | 3.9 | 19.4 | 4.2 |
| Placebo | 16.9 | 5.2 | 28.1 | 4.6 | 7.3 | 4.7 |
| Steroid Inj | 78.9 | 2.1 | 62.7 | 2.9 | 68.4 | 2.3 |
| Steroid Inj+Exe | 70.6 | 2.5 | 71.4 | 2.4 | ||
Surface under cumulative ranking curve (SUCRA) values (0 – 100) and mean ranks are presented, based on a simulation with 1000 replications. Higher SUCRAs and lower mean ranks indicate better performing treatments.
ESWT, extracorporeal shockwave therapy; Exe, exercise; Orthoses, prefabricated or customised foot orthoses; Placebo, usual care/placebo; Steroid Inj, corticosteroid injection; Steroid Inj+Exe, corticosteroid injection combined with exercise.